Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Jabil (JBL) To Report Q1 Earnings: What's In The Cards?

Published 12/12/2019, 09:18 PM
Updated 07/09/2023, 06:31 AM

Jabil (NYSE:JBL) is set to report first-quarter fiscal 2020 results on Dec 17.

For first-quarter fiscal 2020, Jabil expects total revenues between $6.65 billion and $7.35 billion.

Diversified Manufacturing Services (DMS) revenues are forecast to be $3.1 billion, up roughly 3% year over year. Electronics Manufacturing Services (EMS) revenues are forecast to be $3.9 billion, up nearly 11% year over year.

Moreover, the company’s core earnings are expected between 82 cents and $1.04 per share on a non-GAAP basis.

The Zacks Consensus Estimate for earnings stayed at 94 cents over the past 30 days. The consensus mark for revenues is pegged at $6.96 billion, indicating growth of 6.93% from the year-ago quarter’s reported figure.

In fourth-quarter fiscal 2019, the company reported adjusted earnings of 88 cents per share, which beat the Zacks Consensus Estimate by a couple of cents and improved 25.7% year over year.

Revenues increased 13.9% year over year to $6.57 billion, which was within management’s guided range of $6.3-$6.9 billion. However, the figure lagged the Zacks Consensus Estimate of $6.61 billion.

Notably, the company’s earnings beat the Zacks Consensus Estimate in the trailing four quarters, the average positive surprise being 3.73%.

Let’s see how things have shaped up for this announcement.

Jabil, Inc. Price and EPS Surprise

Jabil, Inc. price-eps-surprise | Jabil, Inc. Quote

Factors to Watch

Jabil’s fiscal first-quarter results are expected to have benefited from contract wins in healthcare, automotive, cloud and 5G. Moreover, improving end-market diversification is expected to have been a key catalyst.

The DMS segment is likely to have benefited from an improved business mix, driven by Jabil’s impressive diversification efforts. EMS growth is expected to have been driven by new business wins in 5G wireless, cloud and automotive end markets.

However, performance of Jabil’s DMS segment is expected to have suffered due to a soft mobility business and sluggish spending in the semiconductor capital equipment business. Moreover, increasing competition in the industry is expected to have weighed on margins.

Key Developments in Q1

Eguana announced that it has inked a multi-year master supply agreement with Jabil to manufacture its residential and commercial energy storage systems. Jabil will initially focus on QCELLS Enduro production.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

What Our Model Says

According to the Zacks model, the right combination of two key ingredients — a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — increases the odds of a positive earnings surprise.

Jabil has an Earnings ESP of 0.00% and a Zacks Rank #3, which makes surprise prediction difficult. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Stocks With the Favorable Combination

Here are some stocks you may consider, as according to our proven model, these have the right mix of elements to beat estimates this time around.

Perficient, Inc. (NASDAQ:PRFT) presently has an Earnings ESP of +2.17% and a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Pfizer Inc. (NYSE:PFE) currently has an Earnings ESP of +1.75% and a Zacks Rank of 2.

Cloudera, Inc. (NYSE:CLDR) has an Earnings ESP of +4.55% and a Zacks Rank of 2.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Pfizer Inc. (PFE): Free Stock Analysis Report

Perficient, Inc. (PRFT): Free Stock Analysis Report

Jabil, Inc. (JBL): Free Stock Analysis Report

Cloudera, Inc. (CLDR): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.